DALLAS & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the University of Miami Miller School of Medicine and co-sponsored by the company. The results showed a […]
Other News
iVascular EffPAC 6 Months Outstanding Data Presented at CIRSE 2017 DCB Session
By Anastasia Perebeynos Copenhagen – September 18, 2017 – iVascular SLU data announced today, demonstrate the efficacy of the Luminor drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The 6 months results from the full clinical cohort of the EffPAC randomized study were presented in the DCB session at the […]
Terumo Launches QuiremSpheres® Microspheres in Europe
TOKYO, JAPAN – September 19, 2017 – Terumo Corporation (TSE: 4543) announced today that it has launched QuiremSpheres® microspheres on September 18 in Europe. QuiremSpheres® are available in Europe with plans for expansion its sales area outside of Europe in the future. QuiremSpheres®, the next generation of SIRT microspheres, are […]
Innovative implant for occlusion of heart defects
CARAG Completes CE Marking for its Breakthrough Carag Bioresorbable Septal Occluder (CBSO) Innovative bioresorbable implant of Carag removes risks associated with conventional metal frameworks and expands treatment options for patients with heart defects. CARAG AG, a privately held medical device development company, today announced that it has completed CE (Conformité […]
Boston Scientific (BSX) Announces Positive Late-Breaking Clinical Trial Data For The Heartlogic Heart Failure Diagnostic
DALLAS and MARLBOROUGH, Mass., Sept. 19, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure (HF) decompensation. Data from the study were presented as a late-breaking clinical […]
Cardihab Cardiac Rehab App Spun Out Of CSIRO Ehealth Division
BRISBANE, Australia–(BUSINESS WIRE)–An Australian solution to dramatically improve recovery from a heart attack today became reality. Cardihab’s technology platform was developed by scientists at the Australian eHealth Research Centre (AEHRC), a joint venture between CSIRO and the Queensland Government. Cardihab was spun-out from CSIRO after raising venture capital investment of […]
MiCell Has significant raise for MiStent
Micell raises $62m for MiStent SES SEPTEMBER 19, 2017 BY BRAD PERRIELLO, Drug Delivery Business News Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors. Paris-based Micell makes the MiStent SES sirolimus-eluting absorbable polymer coronary stent, designed to treat coronary artery […]
Meta-Analysis Shows RenalGuard(R) Offers Dramatic Benefit for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Cardiovascular Interventions
MILFORD, MA–(Marketwired – September 13, 2017) – A new meta-analysis suggests that the use of the RenalGuard System® reduces the rate of contrast-induced acute kidney injury (CI-AKI) compared to standard intravascular volume expansion in moderate-to-high-risk patients with chronic kidney disease who are undergoing cardiac interventional procedures. The study, published in the Journal […]
New Study Shows That Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality Associated with Transcatheter Aortic Valve Replacement (TAVR)
SANTA ROSA, Calif.–(BUSINESS WIRE)–Claret Medical® today announced publication of a new study in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions that underscores the role of the Sentinel Cerebral Protection System (CPS) in significantly reducing the early occurrence of stroke associated with transcatheter aortic valve replacement (TAVR). The study […]
2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction
The 2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction, developed in collaboration with the ACC, AHA, APHRS, ASA, EHRA, IDSA, LAHRS, PACES, and STS, is intended to help clinicians in their decision-making process for managing leads and builds on the 2009 Transvenous Lead Extraction: Heart Rhythm Society Expert […]



